Search

Development of Technologies that Address the Complex Architecture of the Face During the Treatment of Severe Facial Burn Injury

Company: KeraNetics, LLC Agency/Program/Year/Phase: DOD / SBIR / 2014 / 1
Abstract: …ovative 3D printed halofuginone eluding keratin-based wound dressing that could potentially improve healing rates and reduce scarring and contracture in our burned Wounded Warriors. The proposed dressing will be formulated and tested for mechanical properties and drug delivery… more

UV IR Image Combiner

Company: Physical Optics Corporation Agency/Program/Year/Phase: DOD / SBIR / 2014 / 2
Abstract: … structures and biological tissue, industrial inspection equipment for product verification and test, laser machining and drilling, microlithography, tissue welding and wideband imaging systems. Potential customers include aerospace, biomedical, pharmaceuticals,… more

Development of Technologies that Address the Complex Architecture of the Face During the Treatment of Severe Facial Burn Injury

Company: Applied Tissue Technologies LLC Agency/Program/Year/Phase: DOD / SBIR / 2014 / 1
Abstract: … (PWD) to be applied to severe facial burns, by a medic, at the time and site of injury. The PWD will envelop the head and form an enclosed treatment chamber that will enable immediate topical delivery of high-dose antibiotics, analgesics and anti-inflammatory drugs. Negative… more

Enhancing the Pharmacokinetic Profile of Protein-based Drugs

Company: Extend Biosciences Inc. Agency/Program/Year/Phase: DOD / SBIR / 2014 / 2
Abstract: Many protein-based drugs have limited efficacy due to a short half-life or require intravenous delivery because of low bioavailability. Extend Biosciences is developing proprietary carrier molecules that allow proteins to access an intrinsic transport pathway for efficient… more

A mechanism-based computational tool to optimize pulmonary drug delivery

Company: 3DT HOLDINGS, LLC Agency/Program/Year/Phase: HHS / SBIR / 2013 / 1
Abstract: DESCRIPTION (provided by applicant): Coronary artery disease (CAD) is a national and worldwide epidemic that places the largest clinical and economic burden on the healthcare system of any disease condition. Patients with stable and acute coronary conditions are often treated with percutaneous… more

Expanding Precision Particle Fabrication Technology for the Widespread Control of

Company: ORBIS BIOSCIENCES, INC. Agency/Program/Year/Phase: HHS / SBIR / 2013 / 2
Abstract: DESCRIPTION (provided by applicant): A critical need currently exists in the pharmaceutical market for microparticles that can accurately and effectively control the release of poorly water-soluble compounds. Although these poorly water-soluble drugs areprojected to have high… more

A Human Fc Bifunctional Fusion Protein to Treat Severe Allergic Asthma

Company: TUNITAS THERAPEUTICS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2013 / 2
Abstract: … plus down-regulation of afferent phase IgE antibody production. This phase 2 proposals comprises complimentary mechanism-of action experiments, efficacy studies and critical preclinical activities that are expected to provide a strong Investigational New Drug (IND… more

SBIR Phase I: Controlled Drug Release from and Degradation of PEG-Hydrogels

Company: ProLynx LLC Agency/Program/Year/Phase: NSF / SBIR / 2013 / 1
Abstract: … are independently predictable, simple to control, and do not show the initial bursts of drug release or terminal drug-dumping characteristic of encapsulating systems. Commercial success will be achieved by a) partnerships where we use our technology for proprietary drugs of … more

Body Worn EMG Controlling of Assistive Robotic Arm for Stroke Rehabilitation

Company: CARE TEAM SOLUTIONS, LLC Agency/Program/Year/Phase: HHS / SBIR / 2013 / 1
Abstract: …, reminders, monitors, and usage communicators have enabled an array of home health aids to support users and caregivers in pill management and monitoring. Beyond bulk pills, additional medication forms, such as topicals, are gaining popularity in unique drug delivery… more

System for PCS Agencies to Monitor, Investigate and Respond to Elder Safety Risks

Company: ADVANCED GENOMIC TECHNOLOGY, LLC Agency/Program/Year/Phase: HHS / SBIR / 2013 / 1
Abstract: … (FTD), Lewy body (LBD), and Parkinson's disease (PD) with dementia (PDD). Success of this project will provide blood miRNA-based diagnostics for MCI, and predict conversion from MCI to AD, unprecedented tests to monitor disease onset, progression, and drug… more

Imaging Software of Functional Connectivity MRI for Alzheimer's Disease

Company: BRAINSYMPHONICS, LLC Agency/Program/Year/Phase: HHS / SBIR / 2013 / 2
Abstract: … Connectivity MRI for Alzheimer's Disease , is written in response to (PA-11-134) Lab to Marketplace: Tools for Brain and Behavioral Research (SBIR [R43/R44]) . Alzheimer's disease (AD) is the most common form of dementia. However, developing drugs that… more

Urinary Biomarkers of Renal Mitochondrial Dysfunction

Company: SCHNELLGEN, INC. Agency/Program/Year/Phase: HHS / STTR / 2013 / 1
Abstract: DESCRIPTION (provided by applicant): The long-term goal of this project is to identify and validate biomarkers of mitochondrial dysfunction due to environmental stressors. Diverse acute insults from surgery, trauma, ischemia/reperfusion (I/R) and drug andenvironmental chemical… more

Genetically-delivered Bevacizumab for Treatment of Wet Age-Related Macular Degene

Company: REGENX BIOSCIENCES, LLC Agency/Program/Year/Phase: HHS / SBIR / 2013 / 1
Abstract: …y system for bevacizumab (anti-VEGF antibody) to treat wet age-related macular degeneration (AMD). The premise is based on: (1)the demonstrated efficacy of monthly intravitreal injections of the monoclonal bevacizumab in treating wet AMD that is accompanied by a high cost of … more

IGF::OT::IGF Aerosolized Delivery of Anti-Tubercular Drugs

Company: PULMOKINE, INC. Agency/Program/Year/Phase: HHS / SBIR / 2013 / 1
Abstract: Develop an inexpensive, easy to use, aerosolized delivery system of a combination of anti-tubercular drugs that could be used for the treatment of multi-drug resistant tuberculosis (MDR TB ). PUBLIC HEALTH RELEVANCE

Relating GPCRs by biased ligands for enhanced therapeutic efficacy

Company: SEACHANGE PHARMACEUTICALS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2013 / 1
Abstract: … trammeled G protein coupled receptors, their discovery is more often serendipitousand few if any predictive computational models exist for it. The field suffers from a paucity of actual biased ligands, whose incompletely explored ranks include even marketed drugs such as… more

A platform to predict side-effect targets for drugs

Company: SEACHANGE PHARMACEUTICALS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2013 / 2
Abstract: DESCRIPTION (provided by applicant): Bioactive small molecules can act on multiple targets, and these off-target activities underlie many of the adverse reactions from which drugs suffer. The motivating idea of this proposal is that these Adverse Drug Reaction (ADR) targets may… more

Holographic Video Display (HVD)

Company: HOLOEYE Systems, Inc. Agency/Program/Year/Phase: DOD / SBIR / 2013 / 1
Abstract: … in standard stereo displays. In this program HSI will study and design key components of this system. As it evolves this holography development will provide new realism to displays including near to eye, multiuser monitors, and projection displays. BENEFIT: Drug creation,… more

Development of a human hepatocyte predictive pharmacology and toxicology system.

Company: HEMOSHEAR, LLC Agency/Program/Year/Phase: HHS / SBIR / 2013 / 2
Abstract: DESCRIPTION (provided by applicant): There is a critical need to improve the accuracy of preclinical drug efficacy and toxicity screening and testing through the development of human hepatocyte (liver) in vitro culture systems that more effectively mimic the human in vivo… more

Drug candidates that disrupt the NEMO/IKK signaling complex for the treatment of

Company: CARMOT THERAPEUTICS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2013 / 2
Abstract: … Phase II research. First, this proposal will validate an innovative technology for targeting protein-protein interactions by progressively converting a peptide ligand into a smaller more drug-like molecule, thus addressing a major technological gap in pharmaceutical discovery.… more

Continuous Real Time CSF Shunt Flow Monitor ShuntCheck

Company: QR PHARMA INC. Agency/Program/Year/Phase: HHS / SBIR / 2013 / 1
Abstract: …, phosphorylated tau (p-tau) and other neurotoxic proteins including APP and alpha-synuclein (aSYN) which also cause neurodegeneration in Alzheimer's Disease (AD) and Parkinson's Disease (PD), respectively. We have developed the first small molecule drug, Posiphen,… more

Dangerous Drug Prevention Skills for People with Intellectual Disabilities

Company: DOUBLE S INSTRUCTIONAL SYSTEMS Agency/Program/Year/Phase: HHS / SBIR / 2013 / 2
Abstract: DESCRIPTION (provided by APPLICANT): An overlooked, neglected, yet significant problem in the United States today is the use and abuse of tobacco, alcohol, and other drugs by individuals with intellectual disabilities (ID). Increasing numbers of people with ID are living… more

Novel anti-viral agents to treat influenza

Company: ALEXANDER BIODISCOVERIES, LLC Agency/Program/Year/Phase: HHS / SBIR / 2013 / 2
Abstract: … of 2009. The most devastating of these, the 1918 Spanish influenza, was associated with an estimated 40 million deaths worldwide. The annual vaccine for seasonal influenza is only partially effective in prevention of disease. Likewise, currently available anti-influenza drugs… more

Targeted Docetaxel-Nanocolloid for the Treatment of Ovarian Cancer

Company: NEMUCORE MEDICAL INNOVATIONS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2013 / 1
Abstract: … from this unique treatment. Part of the challenge with standard chemotherapeutic agents is the retention and distribution of the agent, which can be solved with the use of the NMI's long circulating nanocolloid technology developed for encapsulating poorly soluble drugs,… more

A Nano-pharmaceutical Platform for Creating Artificial Vaccines

Company: Parabon NanoLabs, Inc. Agency/Program/Year/Phase: DOD / SBIR / 2013 / 2
Abstract: In this project, Parabon NanoLabs will employ its Essemblix(tm) Drug Development Platform, a combination of computer-aided design (CAD) software and DNA nano-fabrication technology, to produce artificial vaccines against the biothreat agent ricin on DNA origami decorated first… more

Exact Statistical Tools for Genetic Association Studies

Company: CYTEL, INC Agency/Program/Year/Phase: HHS / SBIR / 2013 / 2
Abstract: …nt): The overall goal of our research is to develop and extend efficient exact statistical tools for testing genetic association, and to incorporate these methods into existing, widely used software packages that will servethe needs of data analysts in pharmaceuticals,… more